Related Experiment Video
Updated: May 27, 2026
Robust Generation of Hepatocyte-like Cells from Human Embryonic Stem Cell Populations
Published on: October 26, 2011
Robust generation of hepatocyte-like cells from human embryonic stem cell populations
Claire N Medine1, Baltasar Lucendo-Villarin, Wenli Zhou
1Medical Research Council Centre for Regenerative Medicine, University of Edinburgh.
Abstract:
Despite progress in modelling human drug toxicity, many compounds fail during clinical trials due to unpredicted side effects. The cost of clinical studies are substantial, therefore it is essential that more predictive toxicology screens are developed and deployed early on in drug development (Greenhough et al 2010). Human hepatocytes represent the current gold standard model for evaluating drug toxicity, but are a limited resource that exhibit variable function. Therefore, the use of immortalised cell lines and animal tissue models are routinely employed due to their abundance. While both sources are informative, they are limited by poor function, species variability and/or instability in culture (Dalgetty et al 2009). Pluripotent stem cells (PSCs) are an attractive alternative source of human hepatocyte like cells (HLCs) (Medine et al 2010). PSCs are capable of self renewal and differentiation to all somatic cell types found in the adult and thereby represent a potentially inexhaustible source of differentiated cells. We have developed a procedure that is simple, highly efficient, amenable to automation and yields functional human HLCs (Hay et al 2008 ; Fletcher et al 2008 ; Hannoun et al 2010 ; Payne et al 2011 and Hay et al 2011). We believe our technology will lead to the scalable production of HLCs for drug discovery, disease modeling, the construction of extra-corporeal devices and possibly cell based transplantation therapies.
Insights
Developing predictive toxicology screens is crucial for drug development. This study presents a novel method for generating functional human hepatocyte-like cells (HLCs) from pluripotent stem cells (PSCs), offering a scalable and reliable alternative for toxicity testing.
Area of Science:
- Biotechnology
- Stem Cell Biology
- Drug Discovery
Background:
- Drug development faces challenges with unpredicted toxicity, leading to clinical trial failures and high costs.
- Current models like human hepatocytes, cell lines, and animal tissues have limitations in availability, function, and species variability.
- Pluripotent stem cells (PSCs) offer a promising source for generating large quantities of human hepatocyte-like cells (HLCs).
Purpose of the Study:
- To develop a simple, efficient, and automatable method for producing functional human HLCs from PSCs.
- To provide a scalable and reliable cell source for early-stage drug toxicity screening and disease modeling.
Main Methods:
- Utilized pluripotent stem cells (PSCs) as a starting material.
- Developed a novel procedure for differentiating PSCs into functional human hepatocyte-like cells (HLCs).
- Focused on efficiency, simplicity, and amenability to automation in the procedure.
Main Results:
- Successfully generated functional human HLCs from PSCs using the developed procedure.
- The method is highly efficient, simple, and suitable for automation.
- The resulting HLCs represent a potentially inexhaustible and consistent cell source.
Conclusions:
- The developed technology enables the scalable production of functional human HLCs.
- This advancement can significantly improve early-stage drug discovery by providing reliable toxicity screening.
- Potential applications include drug discovery, disease modeling, and cell-based therapies.
